Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Following a delay due to the impacts of COVID, the OPTIMISE trial is now open to recruitment!

Psoriatic arthritis develops in ~15% of people with psoriasis and affects around 150,000 people in the UK. Patients that do not respond to standard arthritis drugs are typically prescribed one of two different types of biologic drugs to treat their arthritis, anti-TNF or IL-17 blockers. Doctors do not currently know how to predict in advance which drug will be the best for each patient. OPTIMISE aims to take the guess work out of treating psoriatic arthritis by testing if high levels of a type of blood cell called Th17 cells predicts how well a patient will respond to each drug. This is approach could ensure that patients receive their best drug first, ensuring their disease is controlled quickly improving quality of life. 

Our first recruiting centre is Oxford University Hospitals NHS Foundation Trust – thank you to the team there for being a participating site. The central trials team will be working hard to get as many sites open as possible in January – watch this space!

Similar stories

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.